Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2012

Open Access 01-12-2012 | Research article

Arctium lappa ameliorates endothelial dysfunction in rats fed with high fat/cholesterol diets

Authors: Yun Jung Lee, Deok Ho Choi, Guk Hyun Cho, Jin Sook Kim, Dae Gill Kang, Ho Sub Lee

Published in: BMC Complementary Medicine and Therapies | Issue 1/2012

Login to get access

Abstract

Background

Arctium lappa L. (Asteraceae), burdock, is a medicinal plant that is popularly used for treating hypertension, gout, hepatitis, and other inflammatory disorders. This study was performed to test the effect of ethanol extract of Arctium lappa L. (EAL) seeds on vascular reactivity and inflammatory factors in rats fed a high fat/cholesterol diet (HFCD).

Method

EAL-I (100 mg·kg−1/day), EAL-II (200 mg·kg−1/day), and fluvastatin (3 mg·kg−1/day) groups initially received HFCD alone for 8 weeks, with EAL supplementation provided during the final 6 weeks.

Results

Treatment with low or high doses of EAL markedly attenuated plasma levels of triglycerides and augmented plasma levels of high-density lipoprotein (HDL) in HFCD-fed rats. Chronic treatment with EAL markedly reduced impairments of acetylcholine (ACh)-induced relaxation of aortic rings. Furthermore, chronic treatment with EAL significantly lowered systolic blood pressure (SBP) and maintained smooth and flexible intimal endothelial layers in HFCD-fed rats. Chronic treatment with EAL suppressed upregulation of intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1, and E-selectin in the aorta. Chronic treatment with EAL also suppressed increases in matrix metalloproteinase (MMP)-2 expression. These results suggested that EAL can inhibit HFCD-induced vascular inflammation in the rat model.

Conclusion

The present study provides evidence that EAL ameliorates HFCD-induced vascular dysfunction through protection of vascular relaxation and suppression of vascular inflammation.
Appendix
Available only for authorised users
Literature
1.
Stokes KY, Cooper D, Tailor A, Granger DN: Hypercholesterolemia promotes inflammation and microvascular dysfunction: role of nitric oxide and superoxide. Free Radic Biol Med. 2002, 33: 1026-1036. 10.1016/S0891-5849(02)01015-8.CrossRefPubMed
2.
Madhani M, Scotland RS, MacAllister RJ, Hobbs AJ: Vascular natriuretic peptide receptor-linked particulate guanylate cyclases are modulated by nitric oxide-cyclic GMP signalling. Br J Pharmacol. 2003, 139: 1289-1296. 10.1038/sj.bjp.0705365.CrossRefPubMedPubMedCentral
3.
Figueroa XF, Poblete MI, Boric MP, Mendizábal VE, Adler-Graschinsky E, Huidobro-Toro JP: Clonidine-induced nitric oxide-dependent vasorelaxation mediated by endothelial alpha(2)-adrenoceptor activation. Br J Pharmacol. 2001, 134: 957-968. 10.1038/sj.bjp.0704320.CrossRefPubMedPubMedCentral
4.
Babaei S, Picard P, Ravandi A, Monge JC, Lee TC, Cernacek P, Stewart DJ: Blockade of endothelin receptors markedly reduces atherosclerosis in LDL receptor deficient mice: role of endothelin in macrophage foam cell formation. Cardiovasc Res. 2000, 48: 158-167. 10.1016/S0008-6363(00)00169-3.CrossRefPubMed
5.
Grossman M, Rader DJ, Muller DW, Kolansky DM, Kozarsky K, Clark BJ, Stein EA, Lupien PJ, Brewer HB, Raper SE: A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med. 1995, 1: 1148-1154. 10.1038/nm1195-1148.CrossRefPubMed
6.
Marsh MM, Walker VR, Curtiss LK, Banka CL: Protection against atherosclerosis by estrogen is independent of plasma cholesterol levels in LDL receptor-deficient mice. J Lipid Res. 1999, 40: 893-900.PubMed
7.
Nishimatsu H, Suzuki E, Satonaka H, Takeda R, Omata M, Fujita T, Nagai R, Kitamura T, Hirata Y: Endothelial dysfunction and hypercontractility of vascular myocytes are ameliorated by fluvastatin in obese Zucker rats. Am J Physiol Heart Circ Physiol. 2005, 288: 1770-1776.CrossRef
8.
Spady DK, Woollett LA, Dietschy JM: Regulation of plasma LDL-cholesterol levels by dietary cholesterol and fatty acids. Annu Rev Nutr. 1993, 13: 355-381. 10.1146/annurev.nu.13.070193.002035.CrossRefPubMed
9.
Skretteberg PT, Grundvold I, Kjeldsen SE, Erikssen JE, Sandvik L, Liestøl K, Erikssen G, Pedersen TR, Bodegard J: HDL-cholesterol and prediction of coronary heart disease: Modified by physical fitness? A 28-year follow-up of apparently healthy men. Atherosclerosis. 2012, 220: 250-256. 10.1016/j.atherosclerosis.2011.10.009.CrossRefPubMed
10.
Andreotti F, Porto I, Crea F, Maseri A: Inflammatory gene polymorphisms and ischaemic heart disease: review of population association studies. Heart. 2002, 87: 107-112. 10.1136/heart.87.2.107.CrossRefPubMedPubMedCentral
11.
Blankenberg S, Barbaux S, Tiret L: Adhesion molecules and atherosclerosis. Atherosclerosis. 2003, 170: 191-203. 10.1016/S0021-9150(03)00097-2.CrossRefPubMed
12.
Park SY, Hong SS, Han XH, Hwang JS, Lee D, Ro JS, Hwang BY: Lignans from Arctium lappa and their inhibition of LPS-induced nitric oxide production. Chem Pharm Bull (Japan). 2007, 55: 150-152. 10.1248/cpb.55.150.CrossRef
13.
Maruta Y, Kawabata J, Niki R: Antioxidative caffeoylquinic acid derivatives in the roots of burdock (Arctium lappa L.). J Agric Food Chem. 1995, 43: 2592-2595. 10.1021/jf00058a007.CrossRef
14.
Iwakami S, Wu JB, Fazuka Y, Sankawa W: Platelet activating factor (PAF) Antagonists contained in medicinal plants: Lignans and sesquiterpenes. Chem Pharm Biol. 1992, 40: 1196-1198. 10.1248/cpb.40.1196.CrossRef
15.
Tamayo C, Richardson MA, Diamond S, Skoda I: The chemistry and biological activity of herbs used in Flor-Essence herbal tonic and Essiac. Phytother Res. 2000, 14: 1-14. 10.1002/(SICI)1099-1573(200002)14:1<1::AID-PTR580>3.0.CO;2-O.CrossRefPubMed
16.
Kang DG, Lee JK, Choi DH, Sohn EJ, Moon MK, Lee HS: Vascular relaxation by the methanol extract of Sorbus cortex via NO-cGMP pathway. Biol Pharm Bull. 2005, 28: 860-864. 10.1248/bpb.28.860.CrossRefPubMed
17.
Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M, Yamauchi T, White MF, King GL: Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest. 1999, 104: 447-457. 10.1172/JCI5971.CrossRefPubMedPubMedCentral
18.
Choi DH, Lee YJ, Kim JS, Kang DG, Lee HS: Cynanchum wilfordii ameliorates hypertension and endothelial dysfunction in rats fed with high fat/cholesterol diets. Immunopharmacol Immunotoxicol. 2012, 34: 4-11. 10.3109/08923973.2011.569889.CrossRefPubMed
19.
Choi DH, Lee YJ, Oh HC, Cui YL, Kim JS, Kang DG, Lee HS: Improved Endothelial Dysfunction by Cynanchum wilfordii in Apolipoprotein E(−/−) Mice Fed a High Fat/Cholesterol Diet. J Med Food. 2011, 10.1089/jmf.2010.1222.
20.
Voelkel NF, Tuder RM: Hypoxia-induced pulmonary vascular remodeling: a model for what human disease?. J Clin Invest. 2000, 106: 733-738. 10.1172/JCI11144.CrossRefPubMedPubMedCentral
21.
Zecchin HG, Priviero FB, Souza CT, Zecchin KG, Prada PO, Carvalheira JB, Velloso LA, Antunes E, Saad MJ: Defective insulin and acetylcholine induction of endothelial cell-nitric oxide synthase through insulin receptor substrate/Akt signaling pathway in aorta of obese rats. Diabetes. 2007, 56: 1014-1024. 10.2337/db05-1147.CrossRefPubMed
22.
Siddiqui AH, Hussain T: Enhanced AT1 receptor-mediated vasocontractile response to ANG II in endothelium-denuded aorta of obese Zucker rats. Am J Physiol Heart Circ Physiol. 2007, 292: 1722-1727.CrossRef
23.
Takase H, Moreau P, Küng CF, Nava E, Lüscher TF: Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency. Hypertension. 1996, 27: 25-31. 10.1161/01.HYP.27.1.25.CrossRefPubMed
24.
Bernal PJ, Leelavanichkul K, Bauer E, Cao R, Wilson A, Wasserloos KJ, Watkins SC, Pitt BR, St Croix CM: Nitric-oxide-mediated zinc release contributes to hypoxic regulation of pulmonary vascular tone. Circ Res. 2008, 102: 1575-1583. 10.1161/CIRCRESAHA.108.171264.CrossRefPubMedPubMedCentral
25.
Gervais M, Pons S, Nicoletti A, Cosson C, Giudicelli JF, Richer C: Fluvastatin prevents renal dysfunction and vascular NO deficit in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2003, 23: 183-189. 10.1161/01.ATV.0000051404.84665.49.CrossRefPubMed
26.
Carvalheira JB, Ribeiro EB, Araújo EP, Guimarães RB, Telles MM, Torsoni M, Gontijo JA, Velloso LA, Saad MJ: Selective impairment of insulin signalling in the hypothalamus of obese Zucker rats. Diabetologia. 2003, 46: 1629-1640. 10.1007/s00125-003-1246-x.CrossRefPubMed
27.
Saad MJ, Velloso LA, Carvalho CR: Angiotensin II induces tyrosine phosphorylation of insulin receptor substrate 1 and its association with phosphatidylinositol 3-kinase in rat heart. Biochem J. 1995, 310: 741-744.CrossRefPubMedPubMedCentral
28.
Whitman SC, Miller DB, Wolfe BM, Hegele RA, Huff MW: Uptake of type III hypertriglyceridemic VLDL by macrophages is enhanced by oxidation, especially after remnant formation. Arterioscler Thromb Vasc Biol. 1997, 17: 1707-1715. 10.1161/01.ATV.17.9.1707.CrossRefPubMed
29.
Gotto AM: Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report. Circulation. 2001, 103: 2213-2218. 10.1161/01.CIR.103.17.2213.CrossRefPubMed
30.
Stein EA, Stroes ES, Steiner G, Buckley BM, Capponi AM, Burgess T, Niesor EJ, Kallend D, Kastelein JJ: Safety and tolerability of dalcetrapib. Am J Cardiol. 2009, 104: 82-91. 10.1016/j.amjcard.2009.02.061.CrossRefPubMed
31.
Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, Rosko K, Chavez-Eng C, Lutz R, Bloomfield DM: Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet. 2007, 370: 1907-1914. 10.1016/S0140-6736(07)61813-3.CrossRefPubMed
32.
Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW, Sisk CM, Mitchel Y, Pasternak RC: Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009, 157: 352-360. 10.1016/j.ahj.2008.09.022.CrossRefPubMed
33.
Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, Schiffrin EL: PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension. 2002, 40: 866-871. 10.1161/01.HYP.0000037969.41360.CC.CrossRefPubMed
34.
Endemann DH, Schiffrin EL: Nitric oxide, oxidative excess, and vascular complications of diabetes mellitus. Curr Hypertens Rep. 2004, 6: 85-89. 10.1007/s11906-004-0081-x.CrossRefPubMed
35.
Vink H, Constantinescu AA, Spaan JA: Oxidized lipoproteins degrade the endothelial surface layer: implications for platelet-endothelial cell adhesion. Circulation. 2000, 101: 1500-1502. 10.1161/01.CIR.101.13.1500.CrossRefPubMed
36.
Entman ML, Youker K, Shappell SB, Siegel C, Rothlein R, Dreyer WJ, Schmalstieg FC, Smith CW: Neutrophil adherence to isolated adult canine myocytes. Evidence for a CD18-dependent mechanism. J Clin Invest. 1990, 85: 1497-1506. 10.1172/JCI114596.CrossRefPubMedPubMedCentral
37.
Scalia R, Salomon MG, Lefer AM: Characterization of thrombin-induced leukocyte endothelial cell interaction in the rat mesenteric microvasculature. Cardiovasc Pathobiol. 1997, 1: 160-166.
38.
Sasakawa T, Sasakawa Y, Masunaga T, Fujitsu T, Hirayama Y, Ohkubo Y, Mutoh S: FK506 suppresses E-selectin, ICAM-1 and VCAM-1 expression on vascular endothelial cells by inhibiting tumor necrosis factor alpha secretion from peripheral blood mononuclear cells. Cytokine. 2005, 29: 67-71. 10.1016/j.cyto.2004.04.006.CrossRefPubMed
39.
Galis ZS, Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002, 90: 251-262.PubMed
40.
Newby AC: Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev. 2005, 85: 1-31. 10.1152/physrev.00048.2003.CrossRefPubMed
41.
Guo H, Shi Y, Liu L, Sun A, Xu F, Chi J: Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice. Arch Med Res. 2009, 40: 345-351. 10.1016/j.arcmed.2009.07.006.CrossRefPubMed
Metadata
Title
Arctium lappa ameliorates endothelial dysfunction in rats fed with high fat/cholesterol diets
Authors
Yun Jung Lee
Deok Ho Choi
Guk Hyun Cho
Jin Sook Kim
Dae Gill Kang
Ho Sub Lee
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2012
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/1472-6882-12-116

Other articles of this Issue 1/2012

BMC Complementary Medicine and Therapies 1/2012 Go to the issue

Research article

Effect of Zingiber officinale R. rhizomes (ginger) on pain relief in primary dysmenorrhea: a placebo randomized trial

Research article

Gene expression profiling of flaxseed in mouse lung tissues-modulation of toxicologically relevant genes

Research article

Protective effect of topical Cordia verbenacea in a rat periodontitis model: immune-inflammatory, antibacterial and morphometric assays

Research article

Immunomodulatory and antitumour effects of abnormal Savda Munziq on S180 tumour-bearing mice

Research article

Antinociceptive effect of ethanolic extract of Selaginella convoluta in mice

Research article

Sesquiterpene lactones isolated from indigenous Middle Eastern plants inhibit tumor promoter-induced transformation of JB6 cells